CurrentUnitedHealthcarePolicy 2025T0493HH

Neurophysiologic Testing and Monitoring

Medical policy governing neurophysiologic/electrodiagnostic testing (EMG, NCS, QST, VEPs, physiologic recording devices, and related technologies) for UnitedHealthcare Commercial and Individual Exchange plans.

Policy Summary

PayerUnitedHealthcare

PolicyNeurophysiologic Testing and Monitoring

Policy CodePolicy 2025T0493HH

Change TypeNo material changes

Effective Date1,2025 May

Next Review Date

Key ActionVerify member-specific benefit plan and prior authorization requirements before requesting coverage for monitoring devices or electrodiagnostic testing.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

Commercial & ExchangeApplies to

0.91Wearable GTCS sensitivity

2.1/24hWearable FAR

multipleUnproven tests listed

38Applicable codes

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Evidence summaries and guideline recommendations

Summary of evidence from peer-reviewed literature and major professional guidelines regarding electrodiagnostic testing and related neurophysiologic modalities.

Nerve conduction studies (NCS) and needle electromyography (EMG): High-quality evidence and multiple professional society recommendations (AANEM) support performing both NCS and needle EMG together for the evaluation of peripheral nerve entrapments, generalized neuropathies, polyneuropathies, neuromuscular junction disorders, myopathies, motor neuron diseases, radiculopathies, plexopathies, traumatic nerve lesions, and for precise localization of muscles for interventions (e.g., botulinum toxin).

Late response testing (F-wave and H-reflex): Considered complementary to standard NCS and may be the only abnormality in some cases; useful for S1 radiculopathy (AANEM).

Situations allowing NCS without needle EMG: Professional guidance states NCS performed without needle EMG should be the exception. Limited circumstances (e.g., patients with lymphedema, on anticoagulants, or when EMG cannot be done) may justify NCS alone for conditions otherwise evaluated with combined testing.

Point-of-care and automatic/portable NCS systems: Evidence is limited and currently considered weak. Preliminary studies show promising correlation with conventional testing for some applications (e.g., diabetic polyneuropathy), but sample sizes are small and clinical-outcome data are insufficient to establish equivalence.

Macro-EMG: Available literature is sparse and of limited quality; current evidence is weak and does not clearly demonstrate impact on management or outcomes.

Quantitative Sensory Testing (QST): Evidence is heterogeneous. Some studies and AAN guidance indicate QST may document sensory changes (e.g., in diabetic neuropathy) but reproducibility and standardization are problematic; insufficient evidence to support routine diagnostic use as a sole test.

Surface electromyography (sEMG) and sEMG-based seizure monitoring: Overall evidence is weak. Systematic reviews and clinical trials show variable performance, high methodological heterogeneity, and limitations (e.g., false alarm rates, device placement issues). The ILAE-IFCN recommends validated wearable devices for automated detection of generalized tonic-clonic seizures (GTCS/FBTCS) in selected safety-sensitive settings but does not endorse current wearables for other seizure types.

Surface mechanomyography (sMMG) with IMU sensors: Few published studies; insufficient evidence to conclude benefit for musculoskeletal assessment or to replace established methods.

Visual evoked potentials (VEP) for glaucoma: Investigational for diagnostic monitoring; evidence does not support routine clinical use for glaucoma diagnosis or monitoring.

Physiologic recording devices and digital biomarkers for movement disorders (wearables, smartphone-based sensors): Studies report feasibility, acceptable reliability, and correlations with clinical scales in Parkinson disease, but evidence that use improves clinical outcomes is lacking; larger, controlled studies are needed.

Guideline synthesis and clinical application: Professional societies (AANEM, AAN, ILAE-IFCN) emphasize integrating history and examination, using EDX testing when medically indicated, and preferring combined NCS + needle EMG performed by qualified personnel. Many alternative/novel testing modalities lack sufficient standardized methods, reproducibility, and outcome data to be considered proven or medically necessary.

Applicable Codes and Device Product Codes

Applicable CPT/HCPCS Codesmixed

0106T	Quantitative sensory testing (QST); testing and interpretation per extremity; using touch pressure stimuli to assess large diameter sensation.
0107T	QST per extremity; using vibration stimuli to assess large diameter fiber sensation.
0108T	QST per extremity; using cooling stimuli to assess small nerve fiber sensation and hyperalgesia.
0109T	QST per extremity; using heat-pain stimuli to assess small nerve fiber sensation and hyperalgesia.
0110T	QST per extremity; using other stimuli to assess sensation.
0464T	Visual evoked potential, testing for glaucoma, with interpretation and report.
0778T	Surface mechanomyography (sMMG) with concurrent application of inertial measurement unit (IMU) sensors for measurement of multi-joint range of motion, posture, and muscle function gait;.
95860	Needle electromyography; extremity with or without related paraspinal areas.
95861	Needle electromyography; 2 extremities with or without related paraspinal areas.
95863	Needle electromyography; 3 extremities with or without related paraspinal areas.

1–10 of 38

1/4

FDA product codes for Quantitative Sensory Testing and nerve conduction devicesmixed

LLN	FDA product code: vibration threshold measurement device / related QST instruments
GXB	FDA product code: esthesiometer / current perception threshold devices
LQW	FDA product code: temperature discrimination test devices
GWI	FDA product code: 2-point discriminator / sensory testing

Point-of-care nerve conduction device product codemixed

JXE	FDA product code for point-of-care nerve conduction devices

Device product codesmixed

JXE	FDA product code for point-of-care nerve conduction devices

inv-20: PKG monitoring wear time

PKG (Personal Kinetigraph) recommended wear time6 to 10 days of continuous wear for ambulatory assessment of Parkinsonian motor symptoms (tremor, bradykinesia, dyskinesia)

Intended monitoring purposeContinuous, objective, ambulatory quantification of movement disorder symptoms and related activity (including during sleep)

FDA clearance detailPKG received FDA 510(k) clearance on August 22, 2014

Typical patient age range in device indicationIntended for use in individuals aged 46–83 years

Provider Requirements, Prior Authorization, and Documentation

Note

Coding Reference and Benefit Determination

The following coding list is provided for reference only. Listing of procedure and diagnosis codes in this policy does not guarantee coverage or payment. Benefit coverage is determined by the member-specific benefit plan document and applicable federal or state mandates. Providers must verify member benefits and applicable mandates before rendering services.

Verify member-specific benefit plan prior to service
In event of conflict, the member-specific benefit plan document governs

Documentation Required

Medical Indication and Qualified Personnel

Electrodiagnostic testing should be medically indicated, performed using appropriate equipment, and conducted by qualified personnel. Needle EMG examinations should be performed by a physician specially trained in electrodiagnostic (EDX) medicine. Nerve conduction studies (NCS) should be performed by a trained physician or a trained individual under the direct supervision of a physician. Collection of clinical and electrophysiologic data must be supervised by the EDX physician; some data collection may be delegated to trained technologists or trainees as permitted by guidance.

Testing must use equipment that assesses all parameters of recorded signals (screening-only equipment is not acceptable)
Physician supervision: direct supervision for NCS; one physician should supervise/perform all components of the exam
Needle EMG must be performed by a trained physician; EDX physician must be immediately available when delegated testing occurs

Prior Authorization

Prior Authorization May Be Required for FDA‑Marketed Monitoring Devices

Prior authorization may be required by the member's benefit plan for certain FDA-marketed monitoring devices (e.g., de novo or 510(k) cleared systems) used for physiologic recording of movement or seizure symptoms. Confirm prior authorization requirements with the member-specific plan before ordering or billing these devices.

Examples of devices that may require prior authorization: SPEACe System/Brain Sentinel (de novo), PKG (510(k)), Kinesia (510(k)), Tremorometer (510(k))
Payers may require prior authorization even for FDA-marketed devices — verify with member plan

Denial Risk

Limited Evidence May Trigger Denial

Coverage may be denied when evidence is limited or insufficient to demonstrate clinical benefit. Technologies and tests identified as unproven or investigational in this policy (for example, non‑invasive automated point‑of‑care NCS that test only distal parameters, many sEMG applications, and certain QST modalities) may be considered not medically necessary and denied.

Non‑invasive automatic/portable point‑of‑care NCS that test only distal motor latencies/conduction velocities — unproven
SEMG and SEMG‑based seizure monitoring systems — overall weak evidence; may trigger denial
QST and related modalities — limited reproducibility and inconsistent evidence; coverage may be limited

Note

Member Benefit Verification Required

Providers must verify member-specific benefits and any applicable federal or state mandates prior to ordering or performing testing or supplying devices. In the event of conflict between this policy and the member-specific benefit plan, the member-specific plan governs.

Check member-specific benefit plan document and applicable mandates before using this policy
Medicare Advantage plans: in absence of NCD/LCD, MAO may have its own coverage determinations

Documentation Required

Documentation and Device Performance Reporting

Documentation accompanying claims must include specifics about the test or device used, testing methodology, and device performance. For QST, documentation should list the specific instrument and methodology, demonstrate a reproducible testing protocol and machine calibration, and include evidence of reproducible results. For wearable or sEMG seizure monitors, document device placement, recorded detection events, false positives/negatives, and any adverse events.

QST: include instrument model, methodology, calibration records, and reproducibility data
Wearable/seizure monitors: document placement, detection performance (detections, false alarms, PPV, FAR), and any device‑related adverse events (e.g., skin irritation)
Include clinical indication, history/physical exam findings, and how test results influenced management

Billing Rule

When NCS Alone Is Acceptable

Nerve conduction studies (NCS) without needle EMG are acceptable in limited circumstances where EMG is contraindicated or not feasible, such as individuals with lymphedema, patients on anticoagulation, or when evaluating for isolated distal entrapment (e.g., suspected carpal tunnel syndrome) where NCS alone can answer the clinical question.

Acceptable scenarios: lymphedema, anticoagulation, evaluation for carpal tunnel syndrome
Separate reporting or isolated NCS without EMG is generally discouraged except in these limited situations

Note

Considerations Before Electrodiagnostic Testing

Prior to electrodiagnostic testing, consider clinical appropriateness based on presentation. For distal symmetric polyneuropathy, EDX testing is more likely indicated when symptoms/signs are moderate to severe, atypical, rapidly progressive, suggest another disorder, or when the etiology is unknown. EDX testing is of low yield when findings are symmetric, distal, predominantly sensory, mild, and there is a known cause (e.g., diabetes) with low suspicion for a coexisting nerve disorder.

Indications supporting EDX testing: moderate–severe symptoms, atypical presentation, rapid progression, unknown etiology, signs suggesting another disorder
Low‑yield situations: mild, symmetric distal sensory findings with known cause

Step Therapy

No specific step therapy requirements are specified in this policy for the technologies discussed. Providers should follow member-specific plan rules if the plan imposes any step therapy or prior authorization requirements.

If the member's plan requires step therapy for a related service or device, follow the plan's process
Verify prior authorization and coverage edits with the member plan

Note

Check Member‑Specific Benefit and Mandates

Before using this policy or relying on it for coverage decisions, check the member-specific benefit plan document and applicable federal or state mandates. UnitedHealthcare may modify policies; this policy is informational and does not replace professional medical judgment.

In case of conflict, the member-specific benefit plan governs
UnitedHealthcare may apply third‑party tools (e.g., InterQual) to assist in administering benefits

Definitions and Device Descriptions

inv-42: Needle EMG

DefinitionElectromyography using needle electrodes inserted through the skin into muscle to evaluate whether weakness is due to nerve, neuromuscular junction, or muscle disorder.

Typical useDiagnose peripheral neuropathy, radiculopathy, myopathy, motor neuron disease, and to localize muscles for treatments such as botulinum toxin injections.

Performance requirementNeedle EMG examinations should be performed by a physician specially trained in electrodiagnostic medicine and interpreted in real time.

Related testsOften performed in conjunction with nerve conduction studies (NCS) and may include sampling of proximal and distal muscles to exclude neuropathy or myopathy.

inv-43: Surface EMG (SEMG)

DefinitionSurface EMG (SEMG): electrodes placed on the skin to measure electrical activity of underlying muscle, including paraspinal SEMG and SEMG-based seizure monitoring systems.

ApplicationsUsed for diagnostic recordings (electromyogram), paraspinal evaluation for back pain, and as the signal source for wearable SEMG seizure monitoring systems (e.g., SPEACe).

Evidence noteOverall evidence for many SEMG applications and SEMG-based seizure monitoring systems is weak; further robust studies are needed before broad coverage is supported.

inv-44: Nerve Conduction Studies (NCS)

DefinitionNerve conduction studies (NCS) assess conduction velocity, latency, amplitude, and waveform shape of peripheral nerves to diagnose peripheral nervous system disorders.

Common practiceA properly performed electrodiagnostic evaluation typically includes both NCS and needle EMG (AANEM guidance).

Late responsesLate response testing (F-wave, H-reflex) complements NCS and may be performed during the same evaluation; in some cases late responses may be the only abnormality.

inv-45: Quantitative Sensory Testing (QST)

DefinitionQuantitative Sensory Testing (QST): objective assessments of peripheral sensory function using stimuli such as vibration, touch-pressure, heat, or cold.

ModalitiesIncludes monofilament testing, vibration (Biothesiometer), computer-assisted systems (CASE IV, Medoc), current perception threshold (CPT/sNCT), and pressure-specified sensory devices.

Evidence noteOverall evidence for QST is weak; further studies are needed to establish consistent patient-relevant outcomes and diagnostic utility.

inv-46: Multifocal VEP (mfVEP)

DefinitionMultifocal visual evoked potential (mfVEP): a VEP variation that assesses many visual field locations independently and concurrently to produce a topographical representation of defects.

Use caseInvestigated as a method for diagnosing and monitoring glaucoma by mapping visual field–related cortical responses.

Test characteristicmfVEP provides spatially resolved assessment across multiple visual field locations during a single test session.

inv-47: Macro-EMG

DefinitionMacro-EMG: an electrodiagnostic technique intended to assess the size and features of entire motor units to estimate motor unit loss.

Evidence statementPeer-reviewed evidence is weak and further robust studies are needed to demonstrate consistent patient-relevant outcomes and clinical utility.

Clinical implicationCurrent evidence does not clearly support changes in patient management based on macro-EMG results.

inv-48: GTCS / FBTCS

DefinitionGTCS (generalized tonic-clonic seizures) and FBTCS (focal bilateral tonic-clonic seizures): seizure types for which ILAE-IFCN recommends use of clinically validated wearable detectors when safety concerns exist.

RecommendationILAE-IFCN does not recommend clinical use of currently available wearable devices for seizure types other than GTCS and FBTCS; validated wearables may be used for GTCS/FBTCS when safety concerns exist.

Operational noteUse is especially considered for unsupervised patients who do not share a bedroom and where alarms can result in rapid intervention (within ~5 minutes).

inv-49: QST

DefinitionQST (Quantitative Sensory Testing): psychophysical tests measuring sensory thresholds (vibration, thermal, mechanical) used to assess sensory impairment.

IncludesModalities such as CPT/sNCT, pressure-specified sensory testing, monofilament and computer-assisted examinations.

Evidence noteOverall evidence quality for QST is weak; additional studies are needed to validate diagnostic and prognostic utility.

inv-50: sEMG

DefinitionsEMG (surface electromyography): noninvasive recording of muscle electrical activity using electrodes on the skin, evaluated here for seizure monitoring and respiratory muscle assessment.

Applications reviewedParaspinal SEMG for back pain, SEMG-based seizure monitoring systems (e.g., SPEACe), and other noninvasive monitoring roles.

Evidence noteThe peer-reviewed literature for many sEMG applications is weak; further robust trials and standardization are needed before broad adoption.

inv-51: SPEACe System (Brain Sentinel)

DeviceSPEACe System (Brain Sentinel) — FDA de novo classified wearable sEMG seizure monitoring and alerting system indicated for adjunctive monitoring of signals that may be associated with generalized tonic-clonic seizures when worn over the biceps.

IndicationAdjunctive seizure monitoring in adults at home or in healthcare facilities during periods of rest; alerts caregivers on possible GTC seizures.

Regulatory noteGranted FDA de novo classification (marketing authorization) on February 16, 2017; intended to analyze sEMG signals and provide alarms.

inv-52: PKG (Personal Kinetigraph)

DefinitionPKG (Personal Kinetigraph): a wrist-worn FDA 510(k)-cleared device intended to quantify kinematics of movement disorder symptoms (tremor, bradykinesia, dyskinesia).

Typical use/wear timeWorn continuously for 6 to 10 days to provide ambulatory assessment and activity monitoring, including during sleep.

FDA detailFDA 510(k) clearance date: August 22, 2014.

inv-53: Point-of-care nerve conduction device

DefinitionPoint-of-care nerve conduction device: automated nerve conduction devices regulated under FDA product code JXE as Class II (510(k)) devices.

ExamplesDevices include NC-state System, Brevio NCS-Monitor, and Advance System; distinguishable by testing distal motor latencies, amplitudes, and conduction velocities without real-time waveforms.

Regulatory classificationFDA 510(k) clearance; product code JXE; classified as Class II devices.

inv-54: PKG (Personal KinetiGraph)

DefinitionPersonal KinetiGraph (PKG): a wrist-worn system cleared to quantify kinematics of movement disorder symptoms, provide medication reminders, and event markers for individuals aged 46–83.

Wear timeTypically worn for 6 to 10 days for continuous ambulatory monitoring.

FDA statusReceived FDA 510(k) clearance on August 22, 2014.

inv-55: Embrace

DeviceEmbrace: a wrist-worn device approved as an adjunct for seizure monitoring that senses electrodermal activity (EDA) and motion to detect patterns associated with generalized tonic-clonic seizures.

IndicationAdjunct seizure monitoring in adults at home or in healthcare facilities during periods of rest; device alerts a paired caregiver device when seizure detected.

Regulatory noteReceived FDA approval in January 2018; records accelerometer, EDA, and temperature data for review by trained professionals.

OpenPayer

Neurophysiologic Testing and Monitoring

Coverage Criteria and Evidence Summary

Applicable Codes and Device Product Codes

Provider Requirements, Prior Authorization, and Documentation

Background and Scope

Definitions and Device Descriptions

Policy Revision History